Minimally Invasive Treatment of Lung Cancer Market Report 2025

The minimally invasive treatment of lung cancer market size has grown strongly in recent years. It will grow from $3.06 billion in 2024 to $3.35 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historic period can be attributed to the rising prevalence of lung cancer, increasing awareness of minimally invasive procedures, an expanding geriatric population, greater adoption of early diagnostic methods, and the ongoing development of healthcare infrastructure.

The minimally invasive treatment of lung cancer market size is expected to see strong growth in the next few years. It will grow to $4.78 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to the increasing demand for outpatient procedures, growing investment in specialized lung cancer centers, expanded availability of minimally invasive treatment options, government initiatives supporting advanced healthcare, and a focus on minimizing postoperative complications. Key trends in this period include advancements in surgical instrument technology, innovations in patient monitoring systems, development of precision therapy techniques, research in less invasive interventions, and the integration of artificial intelligence for treatment planning.

The rising prevalence of lung cancer is expected to drive the growth of the minimally invasive treatment of lung cancer market in the coming years. Lung cancer, a disease characterized by uncontrolled cell growth in the lungs, is increasingly common due to higher rates of tobacco smoking, which elevate the risk of tumor formation. Minimally invasive treatments benefit lung cancer patients by removing or destroying tumors through small incisions or imaging-guided probes, reducing recovery time, minimizing damage to healthy lung tissue, lowering complication risks, and enabling patients to resume normal activities sooner. For example, in June 2025, the U.S. Centers for Disease Control and Prevention reported 218,893 new lung cancer cases in 2022, resulting in 131,584 deaths. Consequently, the growing incidence of lung cancer is fueling the minimally invasive treatment market.

Companies in the minimally invasive lung cancer treatment market are focusing on advanced technologies, such as fluoroscopic navigation platforms, to enhance precision and enable targeted therapy. These platforms combine real-time fluoroscopy with navigation technology to guide instruments accurately to targeted lung areas, allowing minimally invasive biopsy and treatment of difficult-to-reach lesions while reducing complications. For instance, in July 2022, Medtronic plc, an Ireland-based medical technology company, performed the first endoluminal lung ablation using the ILLUMISITE platform in Hong Kong. This procedure utilized a customized virtual pathway based on the patient’s CT scan to guide the bronchoscope to the lung lesion, where a specialized ablation catheter delivered targeted therapy, marking a significant advancement in precise, localized lung cancer treatment.

In February 2025, Toulouse University Hospital in France acquired Epione from Quantum Surgical for an undisclosed amount. This acquisition aims to strengthen the hospital’s capacity for minimally invasive, robot-assisted treatment of abdominal and lung tumors, enabling physicians to perform highly precise procedures, improve patient outcomes, reduce recovery times, and expand access to advanced oncological care in the Occitanie region. Quantum Surgical, a France-based medical technology company, specializes in minimally invasive solutions for small and hard-to-reach lung tumors.

Major players in the minimally invasive treatment of lung cancer market are Johnson & Johnson, Medtronic plc, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Intuitive Surgical Inc., Weill Cornell Medicine, Accuray Incorporated, Richard Wolf GmbH, AngioDynamics Inc., CMR Surgical Ltd., Biodesix Inc., Guangzhou Geyi Medical Instrument Co. Ltd., Quantum Surgical SA, Scanlan International Inc., RZ Medizintechnik GmbH & Co. KG, August Reuchlen GmbH, SBH Surgical GmbH & Co. KG, Geister Medizintechnik GmbH.

North America was the largest region in the minimally invasive treatment of lung cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in minimally invasive treatment of lung cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the minimally invasive treatment of lung cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Minimally invasive lung cancer treatment uses small incisions and advanced techniques, such as video-assisted or robotic surgery, to target or remove lung tumors while minimizing damage to surrounding tissues. This method aims to accelerate recovery, reduce complications, and improve patient outcomes compared to conventional open surgery.

The primary types of minimally invasive lung cancer treatments are lung tumor ablation and lung tumor embolization. Lung tumor ablation destroys cancer cells by applying extreme heat or cold directly to the tumor using imaging-guided probes. These treatments are applicable across various stages of lung cancer, including stages I, II, III, and IV, and cover different age groups, such as under 30 years, 31-45 years, and 46-60 years. They are utilized by a range of end users, including hospitals, ambulatory surgical centers (ASCs), specialty clinics, and research institutions.

The minimally invasive treatment for lung cancer market research report is one of a series of new reports that provides minimally invasive treatment for lung cancer market statistics, including minimally invasive treatment for lung cancer industry global market size, regional shares, competitors with the minimally invasive treatment for lung cancer market share, minimally invasive treatment for lung cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the minimally invasive treatment for lung cancer industry. This minimally invasive treatment for lung cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The minimally invasive treatment of lung cancer market consists of revenues earned by entities by providing services such as diagnostic imaging, bronchoscopic procedures, chemotherapy delivery, targeted therapy administration and postoperative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The minimally invasive treatment of lung cancer market also includes of sales of implants, catheters, endoscopes, navigation systems and imaging systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.